Delivery Order SPE2DB22D3301-SPE2DB26FX4KY
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,698.07 to AmerisourceBergen Drug Corp for Trokendi XR 25 mg capsules (30-count units) on October 28, 2025, with completion scheduled for October 29, 2025. This is a firm fixed-price, non-set-aside delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a total value of $999,999,999 and extends through December 2026. The product will...
- The Defense Logistics Agency awarded a $6,530.33 delivery order to AmerisourceBergen Drug Corp for Trokendi XR 200 mg capsules (30-count packaging) under a firm fixed price contract type. The award was made on October 30, 2025, with an ultimate completion date of October 31, 2025, and no set-aside designation was used. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $25,727.33 for Trokendi XR 100 mg capsules (30-count) under a firm fixed-price contract type. This delivery order, issued on August 22, 2025, with an ultimate completion date of August 25, 2025, represents a non-set-aside award made through competitive procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $5,403.67 to AmerisourceBergen Drug Corp for the supply of Trokendi XR 100 mg capsules (30-count) on July 11, 2025, with completion scheduled for July 14, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and...
- The Defense Logistics Agency awarded a delivery order valued at $6,417.22 to AmerisourceBergen Drug Corp for the supply of Trokendi XR 200 mg capsules (30-count) on August 28, 2025, with an ultimate completion date of August 29, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award status. Performance will be executed from the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,966.96 to AmerisourceBergen Drug Corp for the supply of Trokendi XR 100 mg capsules (30-count units) on August 20, 2025, with an ultimate completion date of August 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, performed at the contractor's Conshohocken, Pennsylvania facility. Trokendi XR is a branded anticonvulsant medication commonly used for seizure management and migraine prevention...
- The Defense Logistics Agency awarded a delivery order valued at $1,689.54 to AmerisourceBergen Drug Corp for the supply of Trokendi XR 100 mg capsules (30-count) on July 24, 2025, with completion expected by July 25, 2025. This non-set-aside, firm fixed-price delivery order represents a routine pharmaceutical procurement supporting federal medical supply needs. The award leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Trokendi XR 200 mg capsules (30-count) with a ceiling value of $4,581.65. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The order is set for ultimate completion by November 4, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Trokendi XR 200 mg capsules (30-count units) with a ceiling value of $1,026.44. This firm fixed-price delivery order, with an ultimate completion date of October 21, 2025, represents a non-competitive set-aside delivery against AmerisourceBergen's larger contract vehicle with the agency. The order will be performed at the contractor's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 30, 2025, for the supply of Trokendi XR 25 mg capsules (30-count) valued at $1,476.35. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for completion by May 1, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB26FX4KYDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $25,401.53 to AmerisourceBergen Drug Corp for the supply of Trokendi XR 200 mg capsules (30-count units) under a firm fixed-price contract type. The award was made on November 6, 2025, with an ultimate completion date of November 7, 2025, and does not utilize a set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this contract at its corporate office location. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026. The IDC serves as a global pharmaceutical support mechanism enabling AmerisourceBergen to supply a broad range of medications and medical supplies to military healthcare programs and other federal agencies, including the Defense Health Agency and U.S. Coast Guard. Trokendi XR, an anticonvulsant medication, represents part of the company's extensive portfolio of brand-name and specialty pharmaceuticals delivered through competitive federal procurement. As a major healthcare solutions provider and pharmaceutical distributor, AmerisourceBergen maintains a significant role in supporting federal medical supply chains across multiple therapeutic domains through its established relationship with DLA's medical procurement operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.4k | 11/6/25 |